Literature DB >> 3752975

Factors influencing the in vitro activity of two new aryl-fluoroquinolone antimicrobial agents, difloxacin (A-56619) and A-56620.

L Hirschhorn, H C Neu.   

Abstract

The in vitro activity of difloxacin (A-56619) and A-56620, two new aryl-difluoroquinolones, was decreased by magnesium at 9 mM and in assay at pH 5.5 or in urine. Resistance was seen with members of the family Enterobacteriaceae, Pseudomonas aeruginosa, and Staphylococcus aureus repeatedly exposed to subinhibitory concentrations of the compounds. The frequency of resistance was similar to that found for other new quinolones.

Entities:  

Mesh：

Substances：

Year:  1986        PMID： 3752975      PMCID： PMC176452          DOI： 10.1128/AAC.30.1.143

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  10 in total

1.  In vitro evaluation of A-56619 and A-56620, two new quinolones.

Authors:  A L Barry; C Thornsberry; R N Jones
Journal:  Antimicrob Agents Chemother       Date:  1986-01       Impact factor: 5.191

2.  Ciprofloxacin, a quinolone carboxylic acid compound active against aerobic and anaerobic bacteria.

Authors:  N X Chin; H C Neu
Journal:  Antimicrob Agents Chemother       Date:  1984-03       Impact factor: 5.191

3.  Antibacterial activities of ciprofloxacin, norfloxacin, oxolinic acid, cinoxacin, and nalidixic acid.

Authors:  A L Barry; R N Jones; C Thornsberry; L W Ayers; E H Gerlach; H M Sommers
Journal:  Antimicrob Agents Chemother       Date:  1984-05       Impact factor: 5.191

4.  Method of reliable determination of minimal lethal antibiotic concentrations.

Authors:  R D Pearson; R T Steigbigel; H T Davis; S W Chapman
Journal:  Antimicrob Agents Chemother       Date:  1980-11       Impact factor: 5.191

5.  Selection of multiple antibiotic resistance by quinolones, beta-lactams, and aminoglycosides with special reference to cross-resistance between unrelated drug classes.

Authors:  C C Sanders; W E Sanders; R V Goering; V Werner
Journal:  Antimicrob Agents Chemother       Date:  1984-12       Impact factor: 5.191

6.  In vitro and in vivo activity of DL-8280, a new oxazine derivative.

Authors:  K Sato; Y Matsuura; M Inoue; T Une; Y Osada; H Ogawa; S Mitsuhashi
Journal:  Antimicrob Agents Chemother       Date:  1982-10       Impact factor: 5.191

7.  Open, prospective study of the clinical efficacy of ciprofloxacin.

Authors:  C A Ramirez; J L Bran; C R Mejia; J F Garcia
Journal:  Antimicrob Agents Chemother       Date:  1985-07       Impact factor: 5.191

8.  In vitro activity of enoxacin, a quinolone carboxylic acid, compared with those of norfloxacin, new beta-lactams, aminoglycosides, and trimethoprim.

Authors:  N X Chin; H C Neu
Journal:  Antimicrob Agents Chemother       Date:  1983-11       Impact factor: 5.191

9.  [The antibacterial activity in vitro of ofloxacin in comparison with other orally administered antimicrobial substances on ampicillin-resistant clinical isolates].

Authors:  G Seibert; N Klesel; M Limbert; E Schrinner; I Winkler
Journal:  Arzneimittelforschung       Date:  1984

10.  In vitro activities of the quinolone antimicrobial agents A-56619 and A-56620.

Authors:  G M Eliopoulos; A E Moellering; E Reiszner; R C Moellering
Journal:  Antimicrob Agents Chemother       Date:  1985-10       Impact factor: 5.191
  10 in total
  13 in total

1.  In vitro activity of sparfloxacin.

Authors:  N X Chin; J W Gu; K W Yu; Y X Zhang; H C Neu
Journal:  Antimicrob Agents Chemother       Date:  1991-03       Impact factor: 5.191

2.  In vitro activity of four new quinolones in Mueller-Hinton broth and peritoneal dialysis fluid.

Authors:  C Weissauer-Condon; I Engels; F D Daschner
Journal:  Eur J Clin Microbiol       Date:  1987-06       Impact factor: 3.267

3.  Synergistic interactions of ciprofloxacin and extended-spectrum beta-lactams or aminoglycosides against multiply drug-resistant Pseudomonas maltophilia.

Authors:  A W Chow; J Wong; K H Bartlett
Journal:  Antimicrob Agents Chemother       Date:  1988-05       Impact factor: 5.191

4.  In vitro activities of two novel oxazolidinones (U100592 and U100766), a new fluoroquinolone (trovafloxacin), and dalfopristin-quinupristin against Staphylococcus aureus and Staphylococcus epidermidis.

Authors:  L Mulazimoglu; S D Drenning; V L Yu
Journal:  Antimicrob Agents Chemother       Date:  1996-10       Impact factor: 5.191

5.  Comparative in vitro activity of a new quinolone, AM-1091.

Authors:  H C Neu; A Novelli; N X Chin
Journal:  Antimicrob Agents Chemother       Date:  1989-07       Impact factor: 5.191

6.  In vitro activity of S-ofloxacin.

Authors:  H C Neu; N X Chin
Journal:  Antimicrob Agents Chemother       Date:  1989-07       Impact factor: 5.191

7.  In vitro activity of PD 117596-2, a broad-spectrum difluoroquinolone.

Authors:  H C Neu; N X Chin
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1989-07       Impact factor: 3.267

8.  In vitro activity of the new fluoroquinolone CP-99,219.

Authors:  H C Neu; N X Chin
Journal:  Antimicrob Agents Chemother       Date:  1994-11       Impact factor: 5.191

9.  In vitro activity of temafloxacin, a new difluoro quinolone antimicrobial agent.

Authors:  N X Chin; V M Figueredo; A Novelli; H C Neu
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1988-02       Impact factor: 3.267

10.  In vitro activity of OPC-17116.

Authors:  H C Neu; W Fang; J W Gu; N X Chin
Journal:  Antimicrob Agents Chemother       Date:  1992-06       Impact factor: 5.191
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.